Sugi Predict

Sugi Predict / Compounds / SCHEMBL3334671

SCHEMBL3334671

SCHEMBL3334671

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(C[C@H]2C(=O)N([Si](C)(C)C(C)(C)C)[C@@H]2C(=O)O)ccn1

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ TPSAB1 Q15661 1/20 0.36
▸ TPSD1 Q9BZJ3 1/20 0.36
▸ TPSG1 Q9NRR2 1/20 0.36
▸ F11 P03951 6/20 0.35
▸ PPARG P37231 11/20 0.34
▸ PPARA Q07869 11/20 0.34
▸ CYP2C9 P11712 9/20 0.34
▸ CYP3A4 P08684 8/20 0.34
▸ KCNH2 Q12809 6/20 0.34
▸ SYK P43405 1/20 0.33
▸ CYP2C19 P33261 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13302749 1.00 TPSAB1 (0.36) TPSAB1TPSD1TPSG1F11PPARG
SCHEMBL3335024 1.00 TPSAB1 (0.36) TPSAB1TPSD1TPSG1F11PPARG
SCHEMBL20302528 0.92 F11 (0.35) TPSAB1TPSD1TPSG1F11PPARG
SCHEMBL3334675 0.90 TPSAB1 (0.34) TPSAB1TPSD1TPSG1F11PPARG
SCHEMBL3335028 0.90 TPSAB1 (0.34) TPSAB1TPSD1TPSG1F11PPARG
SCHEMBL13302738 0.89 SYK (0.38) F11SYK
SCHEMBL13302753 0.88 FOLH1 (0.39) F11PPARGPPARACYP2C9CYP3A4
SCHEMBL13899683 0.88 FOLH1 (0.39) F11PPARGPPARACYP2C9CYP3A4
SCHEMBL3334413 0.87 SYK (0.30) F11SYK
SCHEMBL13302671 0.85 SYK (0.32) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214931-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2025-07-03 — — US disclosed
US-12084414-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2024-09-10 — — US disclosed
EP-4309653-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Exithera Pharmaceuticals Inc. (US) 2024-01-24 — — EP disclosed
EP-3102200-B1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS INC (US) 2023-04-05 — — EP disclosed
US-20220281813-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS, INC. 2022-09-08 — — US disclosed
US-11198673-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2021-12-14 — — US disclosed
US-10259785-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2019-04-16 — — US disclosed
US-20180244614-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS, INC. 2018-08-30 — — US disclosed
US-9994521-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2018-06-12 — — US disclosed
US-20170037003-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2017-02-09 — — US disclosed
US-20090143351-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2009-06-04 — — US disclosed
US-20090143351-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2009-06-04 — — US disclosed
US-7501404-B2 Substituted azetidinones DAIMED (US) 2009-03-10 — — US disclosed
US-7501404-B2 Substituted azetidinones DAIMED (US) 2009-03-10 — — US disclosed
US-7501404-B2 Substituted azetidinones DAIMED (US) 2009-03-10 — — US disclosed
EP-1871741-A2 SUBSTITUTED AZETIDINONES Daiamed, Inc. (US) 2008-01-02 — — EP disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 — — US disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 — — US disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 — — US disclosed
WO-2006108039-A2 SUBSTITUTED AZETIDINONES DAIAMED, INC. (US) 2006-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105832-A1 Substituted azetidinones F2R, CPA3, CFD TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885
US-20170037003-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-12084414-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-11198673-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-20220281813-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-10259785-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-20090143351-A1 SUBSTITUTED AZETIDINONES F2R, CPA3, CFD TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885
US-20250214931-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885
US-20180244614-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 TPSAB1 122/4885TPSD1 1027/4885TPSG1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.